Understanding why some people see bigger LDL drops after starting ezetimibe

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pragmatic, open-label study in routine clinical practice looks at adults 18–75 who need additional cholesterol lowering and are starting ezetimibe at standard dose. Researchers will collect baseline clinical data, diet and activity information, and 24-hour urine samples, then measure LDL-C and other lipids after ezetimibe initiation to identify predictors of response. Multivariable analyses will explore how lifestyle and health factors influence LDL reduction, aiming to improve personalized lipid-lowering strategies. The study is single-center and observational, conducted at a Porto-based health unit with Universidade do Porto as lead sponsor.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Age ≥18 and ≤75 years at the time of ezetimibe initiation;
* Initiation of ezetimibe as monotherapy or, in patients already treated with statins or other LDL-C-lowering agents, provided that neither the compound nor the dose of the concomitant LDL-C-lowering therapy was modified at the time of ezetimibe initiation.

Exclusion criteria:

* Absence of indication for ezetimibe therapy as determined by the treating physician;
* Initiation of ezetimibe with concomitant modification of statin or other LDL-C-lowering medication type or dosage;
* Initiation of ezetimibe/statin combination therapy as the first lipid-lowering regimen.

Where it's running

• Unidade Local de Saúde São João
  Porto, Portugal Recruiting

Study contacts

• Study coordinator: Pedro Marques, MD.
• Email: pmmarques@med.up.pt
• Phone: (+351) 220426820

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China

  This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.

  Recruiting Phase 4 Novo Nordisk A/S · Fuyang, Anhui and 25 other locations · NCT07900438

• Zenagamtide vs insulin glargine in type 2 diabetes with heart risk

  This trial tests whether weekly injections of zenagamtide can lower blood sugar and body weight better or differently than insulin glargine in people with type 2 diabetes and high cardiovascular risk who are on 1–3 other diabetes medicines.

  Recruiting at 56 sites Phase 3 Novo Nordisk A/S · Birmingham, Alabama and 329 other locations · NCT07797335

• Health for Hungary: Long-term blood and health data collection to study aging and disease onset

  This study tests whether routine blood tests plus advanced molecular analyses can help detect the early stages of non-communicable diseases in adults over 40.

  Recruiting at 21 sites Center for Molecular Fingerprinting Research Nonprofit LLC · Balatonfüred and 32 other locations · NCT07743021

• Can mouth health and chewing help explain arterial stiffness in healthy adults

  This study tests whether a profile of oral health and function adds information about central arterial stiffness beyond traditional risk factors in healthy adults.

  Recruiting VASCage GmbH · Innsbruck, Tyrol · NCT07736222

• NeoMayor: a smartphone-guided lifestyle program to improve heart health in older adults in Chile

  A smartphone app helps older adults at cardiovascular risk in Chile try better physical activity, diet, sleep, and well-being to see if their heart health improves.

  Recruiting at 2 sites University of Chile · Santiago, Independencia and 1 other locations · NCT07633392

• Dual PCSK9 Inhibition in secondary prevention for high LDL-C with statin intolerance

  This study tests whether combining inclisiran and alirocumab lowers LDL cholesterol better than either drug alone in people with ASCVD who can’t tolerate statins.

  Recruiting Phase 4 University Medical Centre Ljubljana · Ljubljana · NCT07581808

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.